These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17705286)

  • 1. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.
    Ramani K; Miclea RD; Purohit VS; Mager DE; Straubinger RM; Balu-Iyer SV
    J Pharm Sci; 2008 Apr; 97(4):1386-98. PubMed ID: 17705286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.
    Ramani K; Purohit V; Miclea R; Gaitonde P; Straubinger RM; Balu-Iyer SV
    J Pharm Sci; 2008 Sep; 97(9):3753-64. PubMed ID: 18300296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.
    Kosloski MP; Peng A; Varma PR; Fathallah AM; Miclea RD; Mager DE; Balu-iyer SV
    Drug Deliv; 2011 May; 18(4):246-54. PubMed ID: 21114461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of lipidic cochleate containing recombinant factor VIII.
    Miclea RD; Varma PR; Peng A; Balu-Iyer SV
    Biochim Biophys Acta; 2007 Nov; 1768(11):2890-8. PubMed ID: 17936245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model.
    Ramakrishnan R; Balu-Iyer SV
    J Pharm Sci; 2016 Oct; 105(10):3039-3045. PubMed ID: 27431011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.
    Purohit VS; Middaugh CR; Balasubramanian SV
    J Pharm Sci; 2006 Feb; 95(2):358-71. PubMed ID: 16372314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.
    Purohit VS; Balasubramanian SV
    AAPS J; 2006 May; 8(2):E362-70. PubMed ID: 16796387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.
    Miclea RD; Purohit VS; Balu-Iyer SV
    AAPS J; 2007 Jun; 9(2):E251-9. PubMed ID: 17907766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
    Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
    J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.
    Pan J; Liu T; Kim JY; Zhu D; Patel C; Cui ZH; Zhang X; Newgren JO; Reames A; Canivel D; Jesmok G; Pierce GF; Sommer JM; Jiang H
    Blood; 2009 Sep; 114(13):2802-11. PubMed ID: 19654409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.
    Purohit VS; Ramani K; Sarkar R; Kazazian HH; Balasubramanian SV
    J Biol Chem; 2005 May; 280(18):17593-600. PubMed ID: 15728582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.
    Peng A; Straubinger RM; Balu-Iyer SV
    AAPS J; 2010 Sep; 12(3):473-81. PubMed ID: 20517659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.
    Spira J; Plyushch OP; Andreeva TA; Andreev Y
    Blood; 2006 Dec; 108(12):3668-73. PubMed ID: 16888098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.
    Kosloski MP; Miclea RD; Balu-Iyer SV
    AAPS J; 2009 Sep; 11(3):424-31. PubMed ID: 19499345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
    Spira J; Plyushch OP; Andreeva TA; Khametova RN
    Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.